Study of the Use of a Contraceptive Vaginal Ring (NuvaRing) in Normal Daily Practice in Indian Women (P07733)
Study of the Use of a Contraceptive Vaginal Ring (NuvaRing) in Normal Daily Practice in Indian Women (P07733)
This study will collect information on cycle control, acceptability and tolerability of the
 vaginal contraceptive ring (NuvaRing) as used in normal daily practice by Indian women.
Inclusion Criteria:

 -  Women at risk of pregnancy and seeking contraception

 Exclusion Criteria:

 Exclusion criteria based on approved prescribing information in India:

 -  Presence or history of venous thrombosis, with or without pulmonary embolism.

 -  Presence or history of arterial thrombosis (e.g. cerebrovascular accident, myocardial
 infarction) or prodromi of a thrombosis (e.g. angina pectoris or

 transient ischemic attack).

 -  Known predisposition for venous or arterial thrombosis, with or without hereditary
 involvement such as Activated Protein C (APC) resistance, antithrombin-III deficiency,
 protein C deficiency, protein S deficiency, hyperhomocysteinemia and antiphospholipid
 antibodies (anticardiolipin antibodies, lupus anticoagulant).

 -  History of migraine with focal neurological symptoms.

 -  Diabetes mellitus with vascular involvement.

 -  The presence of a severe or multiple risk factor(s) for venous or arterial thrombosis
 (at the discretion of the doctors)

 -  Pancreatitis or a history thereof if associated with severe hypertriglyceridemia.

 -  Presence or history of severe hepatic disease as long as liver function values have
 not returned to normal.

 -  Presence or history of liver tumors (benign or malignant).

 -  Known or suspected malignant conditions of the genital organs or the breasts, if sex
 steroid-influenced.

 -  Undiagnosed vaginal bleeding.

 -  Known or suspected pregnancy.

 -  Hypersensitivity to the active substances or to any of the excipients of NuvaRing.

 -  Women who are breast feeding